This interventional trial (n=5) investigates the safety and feasibility of ketamine-assisted psychotherapy in adolescents with posttraumatic stress disorder (PTSD).
Open-label, single-group pilot study enrolling adolescents (15–17 years) with severe PTSD to evaluate feasibility, tolerability and preliminary efficacy of ketamine-assisted psychotherapy.
Intervention: three intravenous ketamine administrations (0.5 mg/kg, not to exceed 40 mg per dose) administered immediately prior to a psychotherapy session over six weeks; each dosing session followed by 3–6 hours of integration work.
Exploratory assessments include safety/adverse events, PTSD symptom severity at follow-up, feasibility metrics, and seven nights of at-home sleep recordings using a SmartSleep EEG headband.
Three IV ketamine infusions (0.5 mg/kg, max 40 mg) with psychotherapy; at-home SmartSleep EEG recordings.
Each infusion 0.5 mg/kg, not to exceed 40 mg; given immediately prior to psychotherapy session.
SmartSleep EEG recording headband for 7 nights at-home (exploratory sleep measures).